Covalon receives CE marking for Biostep from EU
2008-12-17 11:06 ET - News Release
Dr. Frank DiCosmo reports
COVALON AWARDED CE MARKING FOR COLLAGEN DRESSINGS IN THE EUROPEAN UNION
Covalon Technologies Ltd. has received CE marking for Biostep, collagen dressing.
Dr. Sonia Sanhueza, chief operations officer at Covalon, said: "Our award of CE marking reflects the organization's commitment to manufacture the best of the best in high-quality products for the advanced wound care market. Achieving this important milestone offers Covalon's customers a quality partner that has a demonstrated ability to help them achieve their business initiatives in the EU as well as North America."
CE marking on Biostep:
1. Covalon's declaration that the product complies with the requirements of the European Union's health, safety and environmental protection legislation established by the applicable European standard directives;
2. Indicates that Biostep may be legally placed on the market in the EU;
3. Ensures the free movement of Biostep within the European Free Trade Association (EFTA) (with the exception of Switzerland) and EU single market (total 28 countries).
Dr. Frank DiCosmo, chief executive officer and president of Covalon, commented: "We are very pleased that the company has received CE marking for Biostep collagen wound dressings in the EU. The CE marking enhances the confidence in our advanced collagen wound dressings, improves our product portfolio and marketability. In addition, the CE marking allows our partner, Smith & Nephew, access to the EU marketplace."
Biostep and Biostep Ag are manufactured in the United States by Covalon Technologies, exclusively for Smith & Nephew.
